AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00851370 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Bi-Weekly
Study NCT00289783 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis 792014 vaccine
Description: 3-dose intramuscular injection at 2, 4 and 6 months of age, and 1 booster dose by intramuscular injection at 12 to 15 months of age.
Study NCT02385903 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Flammacerium
Study NCT02385903 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard dressing procedure
Study NCT01735734 — intervention group
Intervention type: DEVICE
Intervention: Air cooling to CM site
Study NCT05793359 — intervention group
Intervention type: DRUG
Intervention: Methylprednisolone
Description: methylprednisolone applied as intravenous infusions or intramuscularly
Study NCT03102450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benzalkonium Chloride Spermicide Cream
Description: One dose of Pharmatex vaginal cream (benzalkonium chloride) must be used systematically before each intercourse, regardless of the cycle period, even during menstrual periods. In case of repeated acts of intercourse, an additional dose of cream must be used before each new act.~Duration of treatment : 6 months (12 months optional)
Study NCT04358146 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Infant formula
Description: Exclusive formula feeding with the new infant formula thickened with fibers
Study NCT04358146 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Infant formula thickened with locust bean gum
Description: Exclusive formula feeding with the formula thickened with locust bean
Study NCT02688270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vascana (0.9% nitroglycerin cream)
Description: Study drug administered topically
Study NCT02688270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vehicle Cream (placebo)
Description: Vehicle administered topically
Study NCT01754246 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 755nm Alexandrite Laser
Description: 755nm Alexandrite laser for treatment of epidermal pigmented lesions and skin toning in Asian skin types
Study NCT05096143 — intervention group
Intervention type: DRUG
Intervention: Sacubitril/valsartan
Description: Participants who were prescribed with Sacubitril/valsartan
Study NCT05096143 — intervention group
Intervention type: DRUG
Intervention: ACEi/ARB
Description: Participants who were prescribed with Angiotensin-converting enzyme inhibitors/Angiotensin II receptor antagonists (ACEi/ARB)
Study NCT03472495 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diltiazem Oral Product
Description: Diltiazem Immediate Release 60 MG PO Q6H (30 MG PO Q6H if patient is \<60 kg)
Study NCT03472495 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diltiazem Injectable Product
Description: Diltiazem Continuous Infusion Titrated
Study NCT03807050 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Astaxanthin
Description: Capsules containing astaxanthin derived from the yeast Phaffia rhodozyma .
Study NCT00749788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JTT-302
Description: JTT-302, 100 mg tablets, 200 mg dose, oral, 30 minutes after the start of the morning meal
Study NCT00749788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JTT-302
Description: JTT-302, 100 mg tablets, 400 mg dose, oral, 30 minutes after the start of the morning meal
Study NCT00749788 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablets, oral, 30 minutes after the start of the morning meal
Study NCT04784793 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: App-based group
Description: Participants received home exercise programs by a postural alignment exercise mobile app we developed.~The postural alignment app included 3 main emerged themes were recorded as self-assessment, neck/shoulder, and upper back-specific exercise content, and motivational notifications.~Participants can evaluate themselves in the application thanks to the self-assessment, receive motivational notifications during the day, and exercise reminders on the days determined by them. They can apply the exercise program with the formed exercise content videos.~The exercise program consists of combined exercises that postural alignment plus exercises of neck spinal stabilization, stretching, and strengthening of neck/shoulders/upper back regions.~Both group participants were requested to do the exercises from the app/brochure 3 times a week, for 6 weeks.
Study NCT04784793 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control group
Description: Participants received home exercise programs as a paper handout.~The exercise program was the same for app-based and control groups.~Both group participants were requested to do the exercises from the app/brochure 3 times a week, for 6 weeks.
Study NCT03930771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1500mg/m2 orally per day (divided into two doses with maximum daily dose of 2500mg) on days 1 through 14.
Study NCT03930771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: 150 to 200 mg/m2 orally on days 10 through 14.
Study NCT00057759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sildenafil citrate
Study NCT00057759 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02285504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAGE-547
Description: Intravenous injection
Study NCT01042938 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Curcumin C3 Complex
Description: Patients take 2.0 grams curcumin (four 500mg capsules) three times daily by mouth for prescribed course of radiation treatment (\~4-7 weeks)
Study NCT01042938 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients take 2.0 grams placebo (four 500mg capsules) three times daily by mouth for prescribed course of radiation treatment (\~4-7 weeks)
Study NCT02520388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLD200 methylphenidate hydrochloride (MPH) Capsules
Description: HLD200 Doses: 40, 60 or 80 mg
Study NCT02520388 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04560686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bintrafusp Alfa
Description: Given IV
Study NCT04560686 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery
Study NCT02445014 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MGH SECM Imaging Capsule
Description: Imaging of the Esophagus using the SECM capsule and SECM Imaging system
Study NCT03506412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entresto™ 49Mg-51 mg tablet
Description: Entresto™ 49Mg-51 mg will be given twice daily orally for 5 weeks
Study NCT00260832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine or Supportive Care
Description: Patient's choice with physician's advice of either supportive care (IV fluids, nutrition, and antibiotics as needed) or cytarabine 20 mg/m\^2 subcutaneously once daily for the first 10 consecutive days of each 28 day cycle, until progression or unacceptable toxicity develops. (These represent one intervention.)
Study NCT00260832 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dacogen (decitabine) only
Description: 20mg/m\^2, 1 hour intravenous (IV) for 5 consecutive days of each 28 day cycle. Cycles continue until disease progression or unacceptable toxicity develops.
Study NCT02594228 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Whey Protein and exercise training
Description: Six meals per day four of which were whole food and two of whey protein for an overall percentage of macronutrient intake of 25% protein and 4 days per week of exercise training
Study NCT02594228 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Food Protein and exercise training
Description: Six meals per day all of which were whole food protein for an overall percentage of macronutrient intake of 25% protein and 4 days per week of exercise training
Study NCT01143909 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: omitting FFP transfusion before an intervention
Description: In the interventional group FFP transfusion is omitted before performing a procedure (e.g. placement of central venous catheter, tracheostomy, chest tube)
Study NCT00119236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tanespimycin
Study NCT00119236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Study NCT03282344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKTR-214
Description: 0.006mg/kg IV on day 1 and every 3 weeks thereafter will be an intravenous (IV) infusion administered over 30 (±5) minutes every 3 weeks.
Study NCT03282344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 360mg (flat dose) IV infusion administered over 30 (±5) minutes every 3 weeks.
Study NCT02018523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: lenalidomide 10mg/day orally until disease progression
Study NCT00255723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV
Study NCT00255723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV
Study NCT00255723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide
Description: Given IV
Study NCT02846792 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT02846792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plinabulin
Description: Given IV
Study NCT01308255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: Prior to week 26~* Infliximab 3mg/kg standard regime (weeks 0, 2, 6, 14, 22)~* Methotrexate commencing at 10mg weekly, progressing to 20mg by week 6.~* Folic acid 5 mg daily except the day methotrexate is taken~Patients will be unblinded at week 26 and then treated pragmatically guided by disease activity
Study NCT01308255 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methylprednisolone
Description: Steroid
Study NCT01308255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: All patients enrolled are commenced on oral methotrexate 10mg once a week The methotrexate dose should be increased to 15 mg at the week 2 visit. The methotrexate should be increased to 20mg at the week 6 visit.
Study NCT01308255 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate
Description: All patients enrolled are commenced on oral methotrexate 10mg once a week The methotrexate dose should be increased to 15 mg at the week 2 visit. The methotrexate should be increased to 20mg at the week 6 visit.
Study NCT01308255 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Folic acid
Description: All patients enrolled are commenced on oral folic acid 5mg daily, except the day methotrexate is taken, and the study infusions.
Study NCT01308255 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Folic acid
Description: All patients enrolled are commenced on oral folic acid 5mg daily, except the day methotrexate is taken, and the study infusions.
Study NCT02749201 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gastrisail
Description: Light Intensity and gastric wall thickness assessment
Study NCT03820336 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Extra Virgin Olive Oil
Description: Subjects will consume 45 ml (40 g) of EVOO daily for 8 weeks.
Study NCT03820336 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control Oil
Description: Subjects will consume 45 ml (40 g) of a control sunflower seed oil daily for 8 weeks.
Study NCT04547998 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control Intervention (UVB)
Description: Targeted narrowband-UVB phototherapy in alignment with published Vitiligo Working Group recommendations.
Study NCT04547998 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational Interventions (Ablative Laser Resurfacing + RECELL + UVB)
Description: Spray-On Skin™ Cells prepared using RECELL will be applied to an area prepared by ablative laser, followed by targeted narrowband UVB phototherapy.
Study NCT04401904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg
Description: 10 participants randomized to receive 12 weeks of daily dapagliflozin 10mg by mouth
Study NCT04401904 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Nutritional counseling
Description: 10 participants randomized to receive 12 weeks of weekly counseling on nutrition
Study NCT00425074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: slow release acetyl salicylic acid
Description: 150 mg in capsules via oral, during 14 days.
Study NCT02539862 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: psychoeducation
Description: the psychoeducation is delivered by a doctor
Study NCT02173717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate
Description: 150 mg Dabigatran etexilate
Study NCT02173717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: 600 mg Rifampicin
Study NCT00425074 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ASA
Description: normal release acetylsalicylic acid
Study NCT00425074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SR-ASA
Description: slow release acetylsalicylic acid 150 mg
Study NCT00282867 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV glucose insulin and potassium, GIK
Description: The treatment intervention includes glucose, insulin, potassium infusion or standard therapy.
Study NCT00282867 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard care
Description: usual care
Study NCT01866345 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgically facilitated Orthodontic treatment
Description: Surgically facilitated Orthodontic treatment in the mandibular anterior region
Study NCT01866345 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional orthodontic treatment
Description: Conventional orthodontic Procedure
Study NCT00981747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: Sildenafil 20mg three times per day for 3 months followed by a one month washout prior to next intervention.
Study NCT02471534 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: abdominal compression
Description: When there are clinical signs of hypovolemia, such as hypotension, decreased urine output and central venous pressure less than 5 mmHg, right upper abdomen is gently compressed for 10 seconds. Changes of blood pressure are continuously recorded during this period. About 3 min later, intravenous colloid fluid 10 mL/kg is infused for 20 min.
Study NCT00981747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: Losartan 25mg two times a day for 3 months followed by a one month washout prior to next intervention.
Study NCT00981747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil and Losartan
Description: Sildenafil 20mg three times per day and Losartan 25mg two times per day followed by a one month washout prior to next intervention.
Study NCT00981747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral Tablet
Description: Placebo pill three times per day for 3 months followed by a one month washout prior to next intervention.
Study NCT01097525 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: WFG PRK
Study NCT00422903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib
Description: 1500 mg administered orally daily
Study NCT00422903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole
Description: 2.5 mg administered orally daily
Study NCT00422903 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: letrozole
Description: 2.5 mg administered orally daily
Study NCT00422903 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 1500 mg administered orally daily
Study NCT01662557 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Family Behavior Modification
Description: 5-month intervention for parents and children providing 15 sessions in behavioral skills training in self monitoring, Traffic Light Diet, goal setting, reinforcement and tasting sessions. Of the 15 sessions, 3 were structured as phone sessions.
Study NCT01097525 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: WFG LASIK
Study NCT01097525 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: WFO PRK
Study NCT01097525 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: WFO LASIK
Study NCT03717714 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Glucosamine 1500 mg
Description: Patients in this group take 3 capsules, each capsule contains Placebo 16.7mg and Glucosamine 500 mg, once a day for 12 weeks
Study NCT03717714 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Polycan 50mg + Glucosamine 750 mg
Description: Patients in this group take 3 capsules, each capsule contains Polycan 16.7mg and Glucosamine 250 mg, once a day for 12 weeks
Study NCT03717714 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Polycan 50mg + Glucosamine 1500 mg
Description: Patients in this group take 3 capsules, each capsule contains Polycan 16.7mg and Glucosamine 500 mg, once a day for 12 weeks
Study NCT04589416 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dental adhesive materials.
Description: It is used to bond the composite resin to the dental tissues. That is, it is used to bond dental filling materials to dental tissues.
Study NCT02782793 — intervention group
Intervention type: PROCEDURE
Intervention: Endoscopic Mucosal Resection
Study NCT02008786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ramipril
Description: 5-10mg (starting dose 5mg titrating up to 10mg if tolerated after 1 week)
Study NCT02008786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rosuvastatin
Description: 10-20mg (suggested dose 10mg for Asians, 20mg for everyone else)
Study NCT02008786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Placebo
Study NCT01662557 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Minimal Nutrition Information
Description: Families assigned to MNI received a series of 15 mailings on topics related identifying a healthy body weight for children; energy balance and calorie requirements for children; MyPyramid for Kids; portion control; the benefits of physical activity and screen-time reduction; encouraging fruit and vegetable consumption; healthy snacks and smart shopping; and encouraging family meals.
Study NCT03775824 — intervention group
Intervention type: DRUG
Intervention: MTX start
Description: Patient prescribed MTX s.c. or p.o. because of active rheumatoid arthritis
Study NCT03775824 — intervention group
Intervention type: DRUG
Intervention: TNF start
Description: Patient prescribed TNF-inhibitor because of active rheumatoid arthritis
Study NCT04165408 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Contino
Description: The Contino® urethral insert is a self-administered licensed medical device, is inserted into the distal portion of the male urethra inhibiting the flow of urine. The Contino is self-inserted into the adult male urethra and is removed prior to urination. Much more than just a device, Contino® is an integrated solution that includes personalised fitting and support from incontinence specialists. It is made from highly specialised medical grade polymer, which has been extensively tested for biocompatibility.
Study NCT02758119 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Serious Game
Study NCT02758119 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Online course
Study NCT00088972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: celecoxib
Description: Given orally
Study NCT00088972 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given orally
Study NCT03558971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cortisol
Description: Participants determine when to administer 5-day regimens of cortisol
Study NCT02961504 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HLCM051
Description: Within 18 to 36 hours after the onset of ischemic stroke, subjects will receive a single dose of 1.2 billion HLCM051 cells to be intravenously administered
Study NCT02961504 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Within 18 to 36 hours after the onset of ischemic stroke, subjects will receive a single dose of placebo to be intravenously administered